AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its primary endpoint.
A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its primary endpoint.
What's Your Reaction?
